Abiopharma

4 Million International VARIZIG Procurement Agreement Procurement Agreement Following a New Tender Won from an International Organization Operating Principally in Latin America Product Supply Expected During the Fourth Quarter of 2022 and the First Half of 2023 Rehovot, Israel, and Hoboken, NJ, July 6, 2022 -- Kamada Ltd. We are extremely pleased with this significant supply agreement, which strongly validates our ability to grow the sales of our newly acquired portfolio of four FDA-approved plasma-derived specialty IgGs in the international markets, said Amir London, Kamadas Chief Executive Officer. 4 MILLION INTERNATIONAL VARIZIG PROCUREMENT AGREEMENT Exhibit 99.